ArticleTherapeutic innovation & regulatory science2018
Translating New Science Into the Drug Review Process: The US FDA's Division of Applied Regulatory Science.
Article in Therapeutic innovation & regulatory science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 37 citations in OpenAlex.
- Potential for Computational Genotoxicity: A Report on Symposium 3 of the 53rd Annual Meeting of the Japanese Environmental Mutagen and Genome Society (JEMS), 2024.Genes and environment : the official journal of the Japanese Environmental Mutagen Society · 2026Article
- Evaluation of a reference antibody panel for prediction of cytokine release in humanised mouse modelsFrontiers in immunology · 2026Article
- Comprehensive bibliographic study of the framework of complex generic drugs.Journal of Taibah University Medical Sciences · 2025Article
- Humanized Mouse Models for Immuno-Oncology Research: A Review and Implications in Lung Cancer Research.JTO clinical and research reports · 2025Review
- Emerging Biomarkers and Determinants of Lipoprotein Profiles to Predict CVD Risk: Implications for Precision Nutrition.Nutrients · 2024Review
- Antibody dependent cellular cytotoxicity-inducing anti-EGFR antibodies as effective therapeutic option for cutaneous melanoma resistant to BRAF inhibitors.Frontiers in immunology · 2024Article
- Humanized mouse models for immuno-oncology research.Nature reviews. Clinical oncology · 2023Review
- How resilient were we in 2021? Results of a LinkedIn Survey including biomedical and pharmaceutical professionals using the Benatti Resiliency Model.Clinical and translational science · 2022Article
- New science, drug regulation, and emergent public health issues: The work of FDA's division of applied regulatory science.Frontiers in medicine · 2022Review
- Emerging technologies and their impact on regulatory science.Experimental biology and medicine (Maywood, N.J.) · 2022Review
- 3D cell culture models: Drug pharmacokinetics, safety assessment, and regulatory consideration.Clinical and translational science · 2021Review
- Regulatory science: The need for empowering Indian innovation.The Indian journal of medical research · 2021Article
- Network model-based screen for FDA-approved drugs affecting cardiac fibrosis.CPT: pharmacometrics & systems pharmacology · 2021Article
- Transitioning to composite bacterial mutagenicity models in ICH M7 (Q)SAR analyses.Regulatory toxicology and pharmacology : RTP · 2019Article
- Principles and procedures for handling out-of-domain and indeterminate results as part of ICH M7 recommended (Q)SAR analyses.Regulatory toxicology and pharmacology : RTP · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2011, the US Food and drug Administration (FDA) developed a strategic plan for regulatory science that focuses on developing new tools, standards, and approaches to assess the safety, efficacy, quality, and performance of FDA-regulated products. In line with this, the Division of Applied Regulatory Science was created to move new science into the Center for Drug Evaluation and Research (CDER) review process and close the gap between scientific innovation and drug review. The Division, located in the Office of Clinical Pharmacology, is unique in that it performs mission-critical applied research and review across the translational research spectrum including in vitro and in vivo laboratory research, in silico computational modeling and informatics, and integrated clinical research covering clinical pharmacology, experimental medicine, and postmarket analyses. The Division collaborates with Offices throughout CDER, across the FDA, other government agencies, academia, and industry. The Division is able to rapidly form interdisciplinary teams of pharmacologists, biologists, chemists, computational scientists, and clinicians to respond to challenging regulatory questions for specific review issues and for longer-range projects requiring the development of predictive models, tools, and biomarkers to speed the development and regulatory evaluation of safe and effective drugs. This article reviews the Division's recent work and future directions, highlighting development and validation of biomarkers; novel humanized animal models; translational predictive safety combining in vitro, in silico, and in vivo clinical biomarkers; chemical and biomedical informatics tools for safety predictions; novel approaches to speed the development of complex generic drugs, biosimilars, and antibiotics; and precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.